Literature DB >> 11956492

Nitric oxide independent activation of guanylate cyclase by YC-1 causes erectile responses in the rat.

H Mizusawa1, P Hedlund, J D Brioni, J P Sullivan, K-E Andersson.   

Abstract

PURPOSE: Activation of soluble guanylate cyclase with a subsequent increase in intracellular levels of cyclic guanosine monophosphate is necessary for normal erection. In vascular tissue 3(5'-hydroxymethyl-2'-furyl-1-benzyl indazole (YC-1) (Abbott Laboratories, North Chicago, Illinois) has been shown to stimulate soluble guanylate cyclase independent of nitric oxide. We studied whether YC-1 modulates erectile responses in the rat.
MATERIALS AND METHODS: The effects of YC-1 given intracavernously or intraperitoneally on intracavernous pressure were investigated in rats. Functional effects of YC-1 on neuronal and endothelial nitric oxide relaxations were studied in 3 x 10(-6) M. 1-noradrenaline contracted preparations of rat isolated corpus cavernosum.
RESULTS: Intracavernous YC-1 (10 micromol. kg.-1) produced erectile responses with a mean intracavernous pressure plus or minus standard error of mean of 81 +/- 17 cm. water (p <0.001) and a mean duration of 7.1 +/- 3.3 minutes (p <0.001). YC-1 (10 micromol. kg.-1) given intraperitoneally also increased the amplitude and duration of erectile responses to cavernous nerve stimulation. Mean peak intracavernous pressure increased from 63 +/- 6 to 10(2) +/- 16 cm. water (p <0.05). Erections induced by a submaximal dose of 25 microg. kg.-1 apomorphine s.c. increased in number after 10 micromol. kg.-1 YC-1 intraperitoneally (p <0.05). In vitro nerve induced relaxant responses were enhanced by increasing concentrations of YC-1. Relaxations at 20 Hz. were increased from a mean of 9% +/- 5% to 52% +/- 5% at a YC-1 concentration of 10(-5) M. (p <0.001). At this concentration carbachol induced relaxations were enhanced from a mean of 19% +/- 3% to 40% +/- 9% (p <0.05).
CONCLUSIONS: YC-1 can evoke erectile responses when given intracavernously and it enhances erections induced by cavernous nerve stimulation and apomorphine when given systemically. In vitro YC-1 enhances electrically evoked relaxations in rat corpus cavernosum. YC-1 represents an interesting pharmacological principle that may be useful for treating erectile dysfunction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11956492

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  14 in total

1.  The Rho-kinase inhibitor Y-27632 and the soluble guanylyl cyclase activator BAY41-2272 relax rabbit vaginal wall and clitoral corpus cavernosum.

Authors:  Selim Cellek
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

Review 2.  [Therapy for organic erectile dysfunction].

Authors:  A J Becker; M Mayer; C G Stief
Journal:  Urologe A       Date:  2005-10       Impact factor: 0.639

Review 3.  NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.

Authors:  Oleg V Evgenov; Pál Pacher; Peter M Schmidt; György Haskó; Harald H H W Schmidt; Johannes-Peter Stasch
Journal:  Nat Rev Drug Discov       Date:  2006-09       Impact factor: 84.694

Review 4.  Stimulators and activators of soluble guanylate cyclase for urogenital disorders.

Authors:  Fabiola Z Mónica; Edson Antunes
Journal:  Nat Rev Urol       Date:  2017-11-14       Impact factor: 14.432

5.  A Review of the Pathophysiology and Novel Treatments for Erectile Dysfunction.

Authors:  George F Lasker; Jason H Maley; Philip J Kadowitz
Journal:  Adv Pharmacol Sci       Date:  2010

Review 6.  Future options for combination therapy in the management of erectile dysfunction in older men.

Authors:  Frank Sommer; Udo Engelmann
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

7.  Analysis of erectile responses to BAY 41-8543 and muscarinic receptor stimulation in the rat.

Authors:  George F Lasker; Edward A Pankey; Alexander V Allain; Jasdeep S Dhaliwal; Johannes-Peter Stasch; Subramanyam N Murthy; Philip J Kadowitz
Journal:  J Sex Med       Date:  2012-09-18       Impact factor: 3.802

Review 8.  Looking to the future for erectile dysfunction therapies.

Authors:  Konstantinos Hatzimouratidis; Dimitrios G Hatzichristou
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Tx2-6 toxin of the Phoneutria nigriventer spider potentiates rat erectile function.

Authors:  K P Nunes; A Costa-Gonçalves; L F Lanza; S F Cortes; M N Cordeiro; M Richardson; A M C Pimenta; R C Webb; R Leite; M E De Lima
Journal:  Toxicon       Date:  2008-02-26       Impact factor: 3.033

Review 10.  Gas what: NO is not the only answer to sexual function.

Authors:  G Yetik-Anacak; R Sorrentino; A E Linder; N Murat
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.